专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20070010433A1 Use of compounds capable of inhibiting the proteolytic processing of semaphorins for prevention, treatment, diagnosis and prognosis of an invasive disease 审中-公开
标题翻译：使用能够抑制信号素的蛋白水解加工的化合物用于预防，治疗，诊断和预后的侵袭性疾病
公开(公告)号：US20070010433A1
公开(公告)日：2007-01-11
申请号：US10520741
申请日：2003-07-10
申请人： Morten Albrechtsen , Claus Christensen , Eugene Lukanidin , Ole Olsen
发明人： Morten Albrechtsen , Claus Christensen , Eugene Lukanidin , Ole Olsen
IPC分类号： A61K38/17
CPC分类号： C07K14/4703 , A61K38/00 , C07K16/18 , G01N33/57484 , G01N33/57488 , G01N2333/4704
摘要： The present invention relates to use of compounds directed to inhibiting expression and/or proteolytic processing semaphorins SEMA3E and/or sema3E and/or activation of a receptor by a proteolytic product of said semaphorins for the manufacture of a medicament for prevention, treatment diagnosis and/or prognosis of an invasive disease. The invention features the compounds selected from the group comprising antisense compounds derived from the sequence of SEMA3E and/or sema3E, peptide compounds derived from the sequence of said semaphorins, anti-bodies against said semaphorins, and peptide compounds derived from the sequence of Plexin A receptor. Furthermore, the invention provides methods for prognosis and/diagnosis of malignancy of cancer based of estimation of the levels of expression and proteolytic processing of said semaphorins in a sample of a tissue or body fluid. The invention also concerns a method for producing an attractant polypeptide by establishing a cleavage product of SEMA3E. and/or sema3E.
摘要翻译：本发明涉及用于抑制表达和/或蛋白水解处理信号素SEMA3E和/或sema3E和/或通过所述信号素的蛋白水解产物激活受体的化合物在制备用于预防，治疗诊断和/ 或侵入性疾病的预后。本发明的特征在于选自衍生自SEMA3E和/或sema3E序列的反义化合物的组合物，衍生自所述信号素序列的肽化合物，针对所述信号素的抗体，以及衍生自Plexin A序列的肽化合物受体。此外，本发明基于对组织或体液样品中所述信号素的表达水平和蛋白水解加工的估计，提供了对癌症恶性程度的预后和/诊断方法。本发明还涉及通过建立SEMA3E的切割产物来产生引诱多肽的方法。和/或sema3E。

2. 发明申请

US20060281130A1 Metod of modulation of interaction between receptor and ligand 审中-公开
标题翻译：受体和配体之间相互作用调制的曲线
公开(公告)号：US20060281130A1
公开(公告)日：2006-12-14
申请号：US10539440
申请日：2003-12-18
申请人： Elisabeth Bock , Vladimir Berezin , Morten Albrechtsen
发明人： Elisabeth Bock , Vladimir Berezin , Morten Albrechtsen
IPC分类号： G01N33/53 , G01N33/574 , A61K38/17 , A61K38/10 , A61K39/395 , A61K31/727 , C07K7/08
CPC分类号： C07K7/06 , A61K38/00 , C07K7/08 , C07K16/22 , G01N33/566 , G01N33/74 , G01N2333/50
摘要： The present invention relates to a method for modulating the interaction between at least two proteins, wherein at least one of the two proteins is a functional cell-surface receptor and the other protein is the receptor ligand. The invention features a binding site of said functional cell-surface receptor on the receptor ligand and discloses a series of amino acid sequences, which are part of the structure of said binding site and/or involved in the interaction between the receptor and the ligand. Moreover, the present invention features methods for molecular design and screening of a candidate compound capable of modulating the interaction between the functional cell-surface receptor and receptor ligand through the described binding site, and provides a screening assay for identification of such a compound. The invention further describes an antibody capable of binding to the above binding site and/or to an epitope comprising an amino acid sequence essential for executing the receptor ligand interaction through said binding site. The invention also concerns a variety of uses of the disclosed methods, peptide sequences and antibodies. The invention in preferred embodiments concerns the binding site of the fibroblast growth factor receptor (FGFR) on FGFR ligands, compounds capable of modulating the receptor ligand interaction through said binding site, and antibody capable of recognition of said binding site.
摘要翻译：本发明涉及调节至少两种蛋白质之间的相互作用的方法，其中两种蛋白质中的至少一种是功能性细胞表面受体，而另一种蛋白质是受体配体。本发明的特征在于所述功能性细胞表面受体在受体配体上的结合位点，并公开了一系列氨基酸序列，其是所述结合位点结构的一部分和/或参与受体和配体之间的相互作用。此外，本发明具有分子设计和筛选能够通过所述结合位点调节功能性细胞表面受体和受体配体之间的相互作用的候选化合物的方法，并提供了鉴定这种化合物的筛选试验。本发明还描述了能够结合上述结合位点和/或包含通过所述结合位点执行受体配体相互作用所必需的氨基酸序列的表位的抗体。本发明还涉及所公开的方法，肽序列和抗体的各种用途。本发明在优选实施方案中涉及成纤维细胞生长因子受体（FGFR）对FGFR配体的结合位点，能够通过所述结合位点调节受体配体相互作用的化合物和能够识别所述结合位点的抗体。

3. 发明申请

US20130042873A1 CONTRACEPTIVE DEVICE 审中-公开
标题翻译：承包设备
公开(公告)号：US20130042873A1
公开(公告)日：2013-02-21
申请号：US13583587
申请日：2011-03-09
申请人： Klaus Bechgaard , Morten Albrechtsen , Galina Skladtchikova
发明人： Klaus Bechgaard , Morten Albrechtsen , Galina Skladtchikova
IPC分类号： A61F6/22 , C08K3/08
CPC分类号： A61F6/22 , A61F6/225
摘要： A composite material for occluding a body lumen comprising at least two different components that differ from each other by their value of elastic modulus is disclosed. One component has a value of elastic modulus of less than 4 GPa, and another component has a value of elastic modulus of above 4 GPa. The component that has a higher value of elastic modulus is embedded in the component that has a lower value of elastic modulus. The composite material comprises at least one portion that is free of the component that has the higher value of elastic modulus, wherein said portion is capable of expanding in at least one direction upon application of pressure perpendicular to the expanding direction, or upon application of heat, light or a chemical or biological impact. The composite material is particular suited for manufacturing implantable contraceptive devices.
摘要翻译：公开了一种用于闭塞体腔的复合材料，其包含通过其弹性模量值彼此不同的至少两个不同组分。一个组分的弹性模量值小于4GPa，另一组分的弹性模量值大于4GPa。具有较高弹性模量值的组分嵌入具有较低弹性模量值的组分中。该复合材料包括至少一部分，该部分不含具有较高弹性模量值的组分，其中所述部分能够在施加垂直于扩展方向的压力时或在施加热量时在至少一个方向上扩展，光或化学或生物影响。复合材料特别适用于制造可植入的避孕装置。

4. 发明申请

US20090105149A1 Compounds comprising lpa 审中-公开
标题翻译：包含lpa的化合物
公开(公告)号：US20090105149A1
公开(公告)日：2009-04-23
申请号：US10567365
申请日：2004-08-06
申请人： Morten Albrechtsen , Elisabeth Bock , Vladimir Berezin , Arne Valdemar Holm
发明人： Morten Albrechtsen , Elisabeth Bock , Vladimir Berezin , Arne Valdemar Holm
IPC分类号： A61K38/10 , C07K7/00
CPC分类号： C07K14/71 , C07K14/70503 , C07K14/78 , C07K19/00
摘要： The present invention relates to new peptide compounds capable of binding to fibroblast growth factor receptor (FGFR), said compounds comprising two individual amino acid sequences, wherein at least one of the two amino acid sequences is capable of binding to FGFR. The invention discloses the amino acid sequences of the compounds and features pharmaceutical compositions comprising thereof. Invention also relates to uses of the compounds and pharmaceutical compositions comprising thereof for the treatment or prevention of different pathological conditions, wherein FGFR plays a role in pathology and/or recovery from the disease. New peptide compounds of the invention are obtainable by the ligand presenting assembly (LPA) method.
摘要翻译：本发明涉及能够结合成纤维细胞生长因子受体（FGFR）的新的肽化合物，所述化合物包含两个单独的氨基酸序列，其中两个氨基酸序列中的至少一个能够结合FGFR。本发明公开了该化合物的氨基酸序列，其特征在于包含其的药物组合物。本发明还涉及包含其的化合物及其药物组合物用于治疗或预防不同病理状况的用途，其中FGFR在疾病的病理学和/或恢复中起作用。本发明的新肽化合物可通过配体呈现组件（LPA）方法获得。

5. 发明授权

US07951906B2 Compounds capable of interacting with a cell-surface fibroblast growth factor receptor 有权
标题翻译：能够与细胞表面成纤维细胞生长因子受体相互作用的化合物
公开(公告)号：US07951906B2
公开(公告)日：2011-05-31
申请号：US12370003
申请日：2009-02-12
申请人： Elisabeth Bock , Vladimir Berezin , Morten Albrechtsen
发明人： Elisabeth Bock , Vladimir Berezin , Morten Albrechtsen
IPC分类号： C07K4/00 , G01N33/53
CPC分类号： C07K7/06 , A61K38/00 , C07K7/08 , C07K16/22 , G01N33/566 , G01N33/74 , G01N2333/50
摘要： The present invention relates to a method for modulating the interaction between at least two proteins, wherein at least one of the two proteins is a functional cell-surface receptor and the other protein is the receptor ligand. The invention features a binding site of said functional cell-surface receptor on the receptor ligand and discloses a series of amino acid sequences, which are part of the structure of said binding site and/or involved in the interaction between the receptor and the ligand. Moreover, the present invention features methods for molecular design and screening of a candidate compound capable of modulating the interaction between the functional cell-surface receptor and receptor ligand through the described binding site, and provides a screening assay for identification of such a compound. The invention further describes an antibody capable of binding to the above binding site and/or to an epitope comprising an amino acid sequence essential for executing the receptor ligand interaction through said binding site. The invention also concerns a variety of uses of the disclosed methods, peptide sequences and antibodies. The invention in preferred embodiments concerns the binding site of the fibroblast growth factor receptor (FGFR) on FGFR ligands, compounds capable of modulating the receptor ligand interaction through said binding site, and antibody capable of recognition of said binding site.
摘要翻译：本发明涉及调节至少两种蛋白质之间的相互作用的方法，其中两种蛋白质中的至少一种是功能性细胞表面受体，而另一种蛋白质是受体配体。本发明的特征在于所述功能性细胞表面受体在受体配体上的结合位点，并公开了一系列氨基酸序列，其是所述结合位点结构的一部分和/或参与受体和配体之间的相互作用。此外，本发明具有分子设计和筛选能够通过所述结合位点调节功能性细胞表面受体和受体配体之间的相互作用的候选化合物的方法，并提供了鉴定这种化合物的筛选试验。本发明还描述了能够结合上述结合位点和/或包含通过所述结合位点执行受体配体相互作用所必需的氨基酸序列的表位的抗体。本发明还涉及所公开的方法，肽序列和抗体的各种用途。本发明在优选实施方案中涉及成纤维细胞生长因子受体（FGFR）对FGFR配体的结合位点，能够通过所述结合位点调节受体配体相互作用的化合物和能够识别所述结合位点的抗体。

6. 发明授权

US06834237B2 Method and system for classifying a biological sample 失效
标题翻译：生物样品分类方法和系统
公开(公告)号：US06834237B2
公开(公告)日：2004-12-21
申请号：US10297187
申请日：2003-04-16
申请人： Lars Noergaard , Morten Albrechtsen , Ole Ingemann Olsen , Niels Harrit , Rasmus Bro-Joergensen
发明人： Lars Noergaard , Morten Albrechtsen , Ole Ingemann Olsen , Niels Harrit , Rasmus Bro-Joergensen
IPC分类号： G01N2164
CPC分类号： G01N21/6486 , A61B5/0059 , A61B5/7232 , A61B5/7267 , G01N21/274 , G01N2021/6417
摘要： The present invention relates to a method of training a classification system for characterising a biological sample, a diagnostic classification system, as well as a method of characterising a condition in an animal or a human being by using parameters obtained from the sample. The invention relates to classification based on physical parameters obtained from luminescence spectroscopy on light emitted from the sample. The data obtained from a spectrofluorimetric analysis can be considered a finger-print of the sample. Each sample gives rise to a unique spectrofluorometric set of physical parameters. By analysing the fluorescence data, it is possible to classify samples into two or more classes based on the fluorescence spectra, such as classifying with respect to presence/abs of a specific disease, group of diseases or risk of later attaining a specific disease or a body condition, or concentration of a specific compound or medicine.
摘要翻译：本发明涉及通过使用从样本获得的参数来训练用于表征生物样品的分类系统，诊断分类系统以及表征动物或人的状况的方法。本发明涉及基于从样品发射的光从发光光谱获得的物理参数的分类。从分光荧光分析获得的数据可以被认为是样品的指纹图。每个样品都产生了独特的荧光光谱的物理参数。通过分析荧光数据，可以基于荧光光谱将样品分类为两个或更多个类别，例如关于特定疾病，疾病组或随后获得特定疾病的风险的存在/ abs的分类，或身体状况或特定化合物或药物的浓度。

7. 发明申请

US20130204121A1 NANOPARTICLE-GUIDED RADIOTHERAPY 审中-公开
标题翻译：纳米指导放射治疗
公开(公告)号：US20130204121A1
公开(公告)日：2013-08-08
申请号：US13810588
申请日：2011-07-15
申请人： Thomas Lars Andresen , Morten Albrechtsen
发明人： Thomas Lars Andresen , Morten Albrechtsen
IPC分类号： A61B6/00 , A61B8/08 , A61B5/055 , A61B5/00 , A61N5/10 , A61B6/03
CPC分类号： A61B6/481 , A61B5/0035 , A61B5/0071 , A61B5/0075 , A61B5/055 , A61B6/032 , A61B6/037 , A61B6/4092 , A61B8/481 , A61K49/0409 , A61K49/0423 , A61K49/0428 , A61N5/1039 , A61N5/1049 , A61N5/1067 , A61N2005/1061 , B82Y5/00
摘要： The present invention relates to a method and nano-sized particles for image guided radiotherapy (IGRT) of a target tissue. More specifically, the invention relates to nano-sized particles comprising X-ray-imaging contrast agents in solid form with the ability to block x-rays, allowing for simultaneous or integrated external beam radiotherapy and imaging, e.g., using computed tomography (CT).
摘要翻译：本发明涉及目标组织的图像引导放射治疗（IGRT）的方法和纳米尺寸颗粒。更具体地，本发明涉及包含固体形式的X射线成像造影剂的纳米尺寸颗粒，具有阻挡X射线的能力，允许同时或集成的外部束放射治疗和成像，例如使用计算机断层摄影（CT）。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式